Inspire Medical Systems vs NovoCure
INSP and NVCR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INSP and NVCR compare
Inspire Medical Systems is the larger company, worth 1.3 times as much as NovoCure ($2.0B against $1.5B).
NovoCure grew revenue faster over the last twelve months (12.9% versus 4.3% for Inspire Medical Systems).
Inspire Medical Systems keeps more of each dollar of sales as profit, with a net margin of 15.0% compared with −16.8% at NovoCure.
Inspire Medical Systems scores higher on the StockData Score (17 against 8 for NovoCure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INSP | NVCR |
|---|---|---|
| Size and price | ||
| Market cap | $2.0B | $1.5B |
| Share price | $68.10 | $13.15 |
| Change, 1 year | −9.4% | −2.4% |
| Change, 5 years | −75.4% | −87.6% |
| Beta (5Y) | 1.07 | 1.58 |
| Employees | 1,333 | 1,605 |
| StockData Score | ||
| Total score | 17 (better) | 8 |
| Valuation score | 4 (better) | 1 |
| Growth score | 3 | 3 |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 14.7× | – |
| P/S | 2.2× | 2.1× (better) |
| P/B | 2.4× (better) | 4.4× |
| EV/EBITDA | 23.1× | – |
| P/FCF | 16.8× | – |
| FCF yield | 5.9% (better) | −1.6% |
| Fair value | $100.68 | $16.42 |
| Margin of safety | 32.4% (better) | 19.9% |
| Growth | ||
| Revenue growth (TTM) | 4.3% | 12.9% (better) |
| Revenue growth, 5Y average | 51.2% (better) | 5.8% |
| Net income growth (TTM) | 154% | – |
| EPS growth (TTM) | 166% | – |
| Profitability | ||
| Gross margin | 86.1% (better) | 77.0% |
| Operating margin | 6.0% (better) | −17.2% |
| Net margin | 15.0% (better) | −16.8% |
| FCF margin | 13.0% (better) | −3.4% |
| Return on equity | 18.0% (better) | −35.2% |
| Return on invested capital | 12.3% (better) | −70.8% |
| Financial health | ||
| Debt / equity | 0.00 | 0.07 (better) |
| Current ratio | 8.55 (better) | 2.49 |
| Altman Z-score | 13.39 (better) | 0.54 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | 5.1% (better) | −0.24% |
| Shareholder yield | 5.1% (better) | −0.24% |
| Ownership | ||
| Held by institutions | 132% | 88.9% |
| Held by insiders | 1.6% | 3.0% |
| Insider net buying, 12 months | −$666K (better) | −$3.3M |
| Short interest, % of float | 14.8% | 9.9% |
Go deeper
- INSP stock overview
- INSP income statement
- INSP valuation and score
- NVCR stock overview
- NVCR income statement
- NVCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.